Publication:
Crosslinked fibroin nanoparticles: Investigations on biostability, cytotoxicity, and cellular internalization

dc.contributor.authorDuy Toan Phamen_US
dc.contributor.authorNuttawut Saelimen_US
dc.contributor.authorRaphaël Cornuen_US
dc.contributor.authorArnaud Béduneauen_US
dc.contributor.authorWaree Tiyaboonchaien_US
dc.contributor.otherUniversité Bourgogne Franche-Comtéen_US
dc.contributor.otherNaresuan Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2020-06-02T04:14:37Z
dc.date.available2020-06-02T04:14:37Z
dc.date.issued2020-01-01en_US
dc.description.abstract© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Recently, crosslinked fibroin nanoparticles (FNP) using the crosslinker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) or the polymer poly(ethylenimine) (PEI) have been developed and showed potentials as novel drug delivery systems. Thus, this study further investigated the biological properties of these crosslinked FNP by labeling them with fluorescein isothiocyanate (FITC) for in vitro studies. All formulations possessed a mean particle size of approximately 300 nm and a tunable zeta potential (−20 to + 30 mV) dependent on the amount/type of crosslinkers. The FITC-bound FNP showed no significant difference in physical properties compared to the blank FNP. They possessed a binding efficacy of 3.3% w/w, and no FITC was released in sink condition up to 8 h. All formulations were colloidal stable in the sheep whole blood. The degradation rate of these FNP in blood could be controlled depending on their crosslink degree. Moreover, no potential toxicity in erythrocytes, Caco-2, HepG2, and 9L cells was noted for all formulations at particle concentrations of < 1 mg/mL. Finally, all FNP were internalized into the Caco-2 cells after 3 h incubation. The uptake rate of the positively charged particles was significantly higher than the negatively charged ones. In summary, the crosslinked FNP were safe and showed high potentials as versatile systems for biomedical applications.en_US
dc.identifier.citationPharmaceuticals. Vol.13, No.5 (2020)en_US
dc.identifier.doi10.3390/ph13050086en_US
dc.identifier.issn14248247en_US
dc.identifier.other2-s2.0-85084252547en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/56137
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084252547&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleCrosslinked fibroin nanoparticles: Investigations on biostability, cytotoxicity, and cellular internalizationen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084252547&origin=inwarden_US

Files

Collections